- Joined
- 25 August 2004
- Posts
- 390
- Reactions
- 0
Me too tarnor - I kept the 1.68's and bought more at 1.40tarnor said:wow didn't see that one coming! seems oversold now with everythings thats been goin on..was hoping for a renetry in the low 1.50s got back in on the bell at 1.40 but will be a little nervouse over the weekend for sure
tanor, I got back in at 1.50 yesterday as well and might buy more on Monday. Biota made an announcement on 16 Sept 2005 on "Reported stockpiling orders". It mentioned "Holland - Order received, but disclosure not allowed at this stage". So far, I have not seen anything about this order yet.tarnor said:wow didn't see that one coming! seems oversold now with everythings thats been goin on..was hoping for a renetry in the low 1.50s got back in on the bell at 1.40 but will be a little nervouse over the weekend for sure
"Oct. 18 (Bloomberg) -- GlaxoSmithKline Plc, Europe's largest drugmaker, will start producing the antiviral medicine Relenza in Australia as concerns rise about the potential of a lethal bird- flu outbreak.Kauri said:I haven't looked into the bio's much and therefore my knowledge is limited to what has been in the press, mainly it seems about the unavailability of anti-virals.
With the reported massive shortfall of supply againt demand for relenza it would seem that BTA needs more production facilities and/or the ability to ramp up existing facilities in the immediate future to meet these large orders. Does anyone know if they have plans to increase production, and more importantly if so, how long before they start producing? Thanks.
chansw said:A new announcement "French Government Confirms Relenza Stockpile of 9 million units" on ASX Web site. Share price up more than 23%
Dr Hamied, however, illustrates his point with the two drugs seen to be effective in treating the symptoms of bird-flu ”” Oseltamivir (marketed by Roche as Tamiflu) and Zanamivir (marketed by GlaxoSmithKline as Relenza).
"They are not sold by their originators. They are in-licensed products," he points out. Roche is paying Gilead a 10 per cent royalty on Tamiflu sales, while GSK pays Biota a seven per cent royalty on Relenza.
"Because we are third world, our prices are low. But I am willing to pay up to four per cent on my net sales to the originator," he argues.
"Mark von Itztein (a co-inventor of zanamivir) says they can cut production time to a few weeks. Most of the current 9 month production time is mucking about with packing and delivery. It is much easier to make than Tamiflu. It is also a much better fit in the virus binding site so you need a tenth as much to be effective and because it fits as designed rather than being forced as Tamiflu is, it does not induce mutational spread. Tamiflu induces resistance because it is a dodgy fit that overlaps a region of the viral protein that is variable while Relenza sits in an invariant region."
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?